Save time and get answers to complex questions with AI chat
Is guselkumab off patent in u s?Lipitor vs generics what's the price gap?What is the difference between apixaban and apixaban accord?When genetic tenofovir alafenamide be available in us?Abbvie humira patent cliff navigation success?
See the DrugPatentWatch profile for Tremfya
Tremfya (guselkumab) received its first FDA approval on February 5, 2019 for the treatment of moderate‑to‑severe plaque psoriasis in adults. Since then it has also been approved for other indications such as plaque psoriasis in children and psoriatic arthritis.
Other Questions About Tremfya :